《BioRxiv,3月31日,Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-04-01
  • Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design

    Jacob Kames, David Dillon Holcomb, Ofer Kimchi, Michael DiCuccio, Nobuko Hamasaki-Katagiri, Tony Wang, Anton A Komar, Aikaterini Alexaki, Chava Kimchi-Sarfaty

    doi: https://doi.org/10.1101/2020.03.30.016832

    Abstract

    As the SARS-CoV-2 pandemic is rapidly progressing, the need for the development of an effective vaccine is critical. A promising approach for vaccine development is to generate, through codon pair deoptimization, an attenuated virus. This approach carries the advantage that it only requires limited knowledge specific to the virus in question, other than its genome sequence. Therefore, it is well suited for emerging viruses for which we may not have extensive data. We performed comprehensive in silico analyses of several features of SARS-CoV-2 genomic sequence (e.g., codon usage, codon pair usage, dinucleotide/junction dinucleotide usage, RNA structure around the frameshift region) in comparison with other members of the coronaviridae family of viruses, the overall human genome, and the transcriptome of specific human tissues such as lung, which are primarily targeted by the virus.

    *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.

  • 原文来源:https://www.biorxiv.org/content/10.1101/2020.03.30.016832v1
相关报告
  • 《BioRxiv,3月31日,Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-01
    • Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2 Xiaoqiang Huang, Robin Pearce, Yang Zhang doi: https://doi.org/10.1101/2020.03.28.013607 Abstract The outbreak of COVID-19 has now become a global pandemic and it continues to spread rapidly worldwide, severely threatening lives and economic stability. Making the problem worse, there is no specific antiviral drug that can be used to treat COVID-19 to date. SARS-CoV-2 initiates its entry into human cells by binding to angiotensin-converting enzyme 2 (hACE2) via the receptor binding domain (RBD) of its spike protein. Therefore, molecules that can block SARS-CoV-2 from binding to hACE2 may potentially prevent the virus from entering human cells and serve as an effective antiviral drug. Based on this idea, we designed a series of peptides that can strongly bind to SARS-CoV-2 RBD in computational experiments. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.
  • 《bioRxiv,6月9日,Structural basis of a public antibody response to SARS-CoV-2》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-06-10
    • Structural basis of a public antibody response to SARS-CoV-2 View ORCID ProfileMeng Yuan, Hejun Liu,  View ORCID ProfileNicholas C. Wu,  View ORCID ProfileChang-Chun D. Lee,  View ORCID ProfileXueyong Zhu,  View ORCID ProfileFangzhu Zhao,  View ORCID ProfileDeli Huang, Wenli Yu, Yuanzi Hua, Henry Tien, Thomas F. Rogers, Elise Landais, Devin Sok, Joseph G. Jardine, Dennis R. Burton, Ian A. Wilson doi: https://doi.org/10.1101/2020.06.08.141267 Abstract Molecular-level understanding of human neutralizing antibody responses to SARS-CoV-2 could accelerate vaccine design and facilitate drug discovery. We analyzed 294 SARS-CoV-2 antibodies and found that IGHV3-53 is the most frequently used IGHV gene for targeting the receptor binding domain (RBD) of the spike (S) protein. We determined crystal structures of two IGHV3-53 neutralizing antibodies +/- Fab CR3022 ranging from 2.33- to 3.11-angstrom resolution. The germline-encoded residues of IGHV3-53 dominate binding to the ACE2 binding site epitope with no overlap with the CR3022 epitope. Moreover, IGHV3-53 is used in combination with a very short CDR H3 and different light chains. Overall, IGHV3-53 represents a versatile public VH in neutralizing SARS-CoV-2 antibodies, where their specific germline features and minimal affinity maturation provide important insights for vaccine design and assessing outcomes.